Promising Results from Athira Pharma's Fosgonimeton

Promising Results from Athira Pharma’s Fosgonimeton

Athira Pharma, Inc. (NASDAQ: ATHA), a leading late-stage biopharmaceutical company dedicated to pioneering small molecules that rejuvenate neurons and decelerate neurodegeneration, has unveiled compelling findings from its SHAPE Phase 2 clinical trial. This trial assessed the potential of fosgonimeton (ATH-1017) in patients grappling with Parkinson’s disease, dementia, and dementia with Lewy bodies. Fosgonimeton Fosgonimeton is a…

Donanemab Results in Cognitive Decline in Alzheimer's Disease

Donanemab Shows Promising Results in Slowing Cognitive Decline in Alzheimer’s Disease

Introduction Eli Lilly recently presented the full results from their Phase 3 TRAILBLAZER-ALZ 2 study at the Alzheimer’s Association International Conference (AAIC). The study focused on evaluating the effectiveness of donanemab, a potential treatment for early symptomatic Alzheimer’s disease (AD). The results, also published in the Journal of the American Medical Association (JAMA), demonstrated that…